The Cabinet trial was a Phase III multi-institutional placebo-controlled trial of cabozantinib versus placebo in patients with neuroendocrine tumors of both pancreatic and extra-pancreatic origin. It was run by Jennifer Chan from the DFCI and the full results were published in 2020 at the New England Journal of Medicine. Cabinet pretty much showed that cabozantinib has efficacy in tumors of both pancreatic and extra-pancreatic origin, with a meaningful prolongation of the progression-free survival, more pronounced in the pancreatic cohort...
The Cabinet trial was a Phase III multi-institutional placebo-controlled trial of cabozantinib versus placebo in patients with neuroendocrine tumors of both pancreatic and extra-pancreatic origin. It was run by Jennifer Chan from the DFCI and the full results were published in 2020 at the New England Journal of Medicine. Cabinet pretty much showed that cabozantinib has efficacy in tumors of both pancreatic and extra-pancreatic origin, with a meaningful prolongation of the progression-free survival, more pronounced in the pancreatic cohort. The trial was actually stopped prematurely after an interim analysis showed significant effect on PFS. What we’re presenting at ASCO today or this weekend is a post hoc analysis on the Cabinet trial where we essentially look at patients and stratify them based on the functional or non-functional status of their tumor. The question is of whether cabozantinib can have a meaningful effect on PFS in patients with both functional and non-functional tumors. What we showed is that it does. In patients with non-functioning tumors, cabozantinib probably triples the PFS, while in patients with functioning neuroendocrine tumors, cabozantinib more than doubles it. So, in a nutshell, it looks like cabozantinib has an effect on patients with neuroendocrine tumors, regardless of the hormonal status.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
